Eli Lilly and Company (LLY) Q1 FY2026 Financials
PeriodQ2 FY2026Q1 FY2026
Archived record for Q1 FY2026. The current period is Q2 FY2026.
Published
Eli Lilly and Company reported $19.80 billion in revenue for Q1 FY2026, the quarter ended March 31, 2026, up 55.5% from a year earlier, and net income of $7.40 billion, up 168.1%. The two tirzepatide medicines carried the quarter: Mounjaro revenue of $8.66 billion was up 125.5% and Zepbound revenue of $4.16 billion was up 79.9%, on much higher volumes that outweighed lower realized prices in the United States and abroad. Diluted earnings per share of $8.26 were up 169.9%, growing faster than revenue because the year-ago quarter carried a far larger charge for acquired in-process research and development and a higher effective tax rate.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $19,799,000,000 | up 55.5% |
| Net income | $7,396,000,000 | up 168.1% |
| Diluted EPS | $8.26 | up 169.9% |
| Mounjaro revenue | $8,662,000,000 | up 125.5% |
| Zepbound revenue | $4,160,000,000 | up 79.9% |
| Gross margin | 81.9% | down 0.6 points |
Company details
| Name | ELI LILLY & Co |
|---|---|
| Ticker | LLY |
| CIK | 0000059478 |
| Exchange | NYSE |
| State | Indiana |
| Incorporation | Indiana |
| SIC | 2834 |
| Office | Life Sciences |
| Industry | Pharmaceutical Preparations |
| Latest period covered | Q1 FY2026, ended 2026-03-31, 10-Q, accession 0000059478-26-000045 |
| Fiscal year end | 12/31 (MM/DD) |
Data files
- Financial statementsPage Annual financial statements plus the latest quarter: income statement, balance sheet, cash flow. Actual dollars, actual shares. Sourcing notes and uncertainties included.
- 10-K and 10-Q summaryPage Qualitative synthesis of the latest 10-K + 10-Q: business, risk factors (quarter-over-quarter changes flagged), MD&A, legal proceedings, subsequent events.
- 8-K filings and eventsPage Digest of material 8-K filings: earnings headlines, management changes, capital-return and financing actions, governance. SEC accession numbers cited throughout.
FAQ · Eli Lilly Q1 FY2026
How much revenue did Eli Lilly report in Q1 FY2026?
Eli Lilly and Company reported $19.80 billion in revenue for Q1 FY2026, the quarter ended March 31, 2026. That is up 55.5% from $12.73 billion in the same quarter a year earlier.
What were Mounjaro and Zepbound sales in Q1 FY2026?
Eli Lilly and Company reported Mounjaro revenue of $8.66 billion and Zepbound revenue of $4.16 billion in Q1 FY2026, up 125.5% and up 79.9% respectively from $3.84 billion and $2.31 billion a year earlier. Together the two tirzepatide medicines were the largest source of the company's $19.80 billion in total revenue for the quarter.
What was Eli Lilly's earnings per share in Q1 FY2026?
Eli Lilly and Company reported diluted earnings per share of $8.26 in Q1 FY2026, up 169.9% from $3.06 a year earlier, on net income of $7.40 billion.
How profitable is Eli Lilly?
Eli Lilly and Company earned $7.40 billion on $19.80 billion of revenue in Q1 FY2026, with a gross margin of 81.9% of revenue, down 0.6 points from a year earlier on lower realized prices.
Where can I get Eli Lilly and Company (LLY) financial data in machine-readable form?
Ticker Scout publishes Eli Lilly and Company's financial statements as JSON at https://tickerscout.ai/lly/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/lly/narrative.md and https://tickerscout.ai/lly/events.md. Eli Lilly and Company's SEC CIK is 0000059478. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
Related companies
How this page was built
This page was built from Eli Lilly and Company's own filings with the SEC, read one at a time, and nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names six such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Data extracted from SEC filings (accession numbers cited in each file). The undated URLs hold the latest period and are replaced in place each quarter; every period also stays published at its own dated URL, which never changes. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.